BRIEF-Emergent Biosolutions Marks 10-Year Anniversary Of The U.S. FDA Approval Of Narcan® Nasal Spray And Reinforces Its Commitment To Increasing Naloxone Access

Reuters

Nov 18

BRIEF-<a href="https://laohu8.com/S/EBS">Emergent Biosolutions</a> Marks 10-Year Anniversary Of The U.S. FDA Approval Of Narcan® Nasal Spray And Reinforces Its Commitment To Increasing Naloxone Access

Emergent BioSolutions Inc EBS.N:

EMERGENT BIOSOLUTIONS MARKS 10-YEAR ANNIVERSARY OF THE U.S. FDA APPROVAL OF NARCAN® NASAL SPRAY AND REINFORCES ITS COMMITMENT TO INCREASING NALOXONE ACCESS

Source text: ID:nGNX90rqpS

Further company coverage: EBS.N

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2584193090"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584193090\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584193090?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584193090","market":"nz","top_or_hot":-1,"title":"BRIEF-Emergent Biosolutions Marks 10-Year Anniversary Of The U.S. FDA Approval Of Narcan® Nasal Spray And Reinforces Its Commitment To Increasing Naloxone Access","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/EBS\">Emergent Biosolutions</a> Marks 10-Year Anniversary Of The U.S. FDA Approval Of Narcan® Nasal Spray And Reinforces Its Commitment To Increasing Naloxone Access</title></head><body><p>Emergent BioSolutions Inc <span>EBS.N</span>:</p><ul><li><p>EMERGENT BIOSOLUTIONS MARKS 10-YEAR ANNIVERSARY OF THE U.S. FDA APPROVAL OF NARCAN® NASAL SPRAY AND REINFORCES ITS COMMITMENT TO INCREASING NALOXONE ACCESS</p></li></ul><p>Source text: <span>ID:nGNX90rqpS</span></p><p>Further company coverage: <span>EBS.N</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Emergent Biosolutions Marks 10-Year Anniversary Of The U.S. FDA Approval Of Narcan® Nasal Spray And Reinforces Its Commitment To Increasing Naloxone Access</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Emergent Biosolutions Marks 10-Year Anniversary Of The U.S. FDA Approval Of Narcan® Nasal Spray And Reinforces Its Commitment To Increasing Naloxone Access\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-18 21:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/EBS\">Emergent Biosolutions</a> Marks 10-Year Anniversary Of The U.S. FDA Approval Of Narcan® Nasal Spray And Reinforces Its Commitment To Increasing Naloxone Access</title></head><body><p>Emergent BioSolutions Inc <span>EBS.N</span>:</p><ul><li><p>EMERGENT BIOSOLUTIONS MARKS 10-YEAR ANNIVERSARY OF THE U.S. FDA APPROVAL OF NARCAN® NASAL SPRAY AND REINFORCES ITS COMMITMENT TO INCREASING NALOXONE ACCESS</p></li></ul><p>Source text: <span>ID:nGNX90rqpS</span></p><p>Further company coverage: <span>EBS.N</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4583","symbol_name":"猴痘概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUA1QZPDQ:1","article_id":"2584193090","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584193090","pubTimestamp":1763471959,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Emergent Biosolutions Marks 10-Year Anniversary Of The U.S. FDA Approval Of Narcan Nasal Spray And Reinforces Its Commitment To Increasing Naloxone AccessEmergent BioSolutions Inc EBS.N:EMERGENT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4583":"猴痘概念","EBS":"Emergent Biosolutions","BK4139":"生物科技"},"translate_title":"BRIEF-Emergent Biosolutions纪念美国FDA批准Narcan 10周年®鼻喷雾剂，并加强其对增加纳洛酮可及性的承诺","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBS":0.9},"content_text":"BRIEF-Emergent Biosolutions Marks 10-Year Anniversary Of The U.S. FDA Approval Of Narcan® Nasal Spray And Reinforces Its Commitment To Increasing Naloxone AccessEmergent BioSolutions Inc EBS.N:EMERGENT BIOSOLUTIONS MARKS 10-YEAR ANNIVERSARY OF THE U.S. FDA APPROVAL OF NARCAN® NASAL SPRAY AND REINFORCES ITS COMMITMENT TO INCREASING NALOXONE ACCESSSource text: ID:nGNX90rqpSFurther company coverage: EBS.N","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}